218 related articles for article (PubMed ID: 30587986)
1. Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.
Wu C; Zhang Y; Yang D; Zhang J; Ma J; Cheng D; Chen J; Deng L
Int J Nanomedicine; 2019; 14():75-85. PubMed ID: 30587986
[TBL] [Abstract][Full Text] [Related]
2. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
3. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
5. Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Bi Y; Lee RJ; Wang X; Sun Y; Wang M; Li L; Li C; Xie J; Teng L
Int J Nanomedicine; 2018; 13():5811-5822. PubMed ID: 30323583
[TBL] [Abstract][Full Text] [Related]
6. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
7. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
Fang YP; Chuang CH; Wu YJ; Lin HC; Lu YC
Int J Nanomedicine; 2018; 13():2789-2802. PubMed ID: 29785106
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
[No Abstract] [Full Text] [Related]
9. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
10. Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation.
He W; Du Y; Wang T; Wang J; Cheng L; Li X
Int J Pharm; 2021 Sep; 606():120856. PubMed ID: 34229071
[TBL] [Abstract][Full Text] [Related]
11. A ROS-response hyaluronic acid-coated/chitosan polymer prodrug for enhanced tumour targeting efficacy of SN38.
Qin J; Sun M; Zhen Y; Li J; Wang D
J Drug Target; 2023 Jul; 31(6):623-633. PubMed ID: 37216422
[TBL] [Abstract][Full Text] [Related]
12. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
[TBL] [Abstract][Full Text] [Related]
13. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
14. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy.
Zheng Y; Yan X; Wang Y; Duan X; Wang X; Chen C; Tian D; Luo Z; Zhang Z; Zeng Y
J Mater Chem B; 2019 Jan; 7(2):265-276. PubMed ID: 32254551
[TBL] [Abstract][Full Text] [Related]
15. Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy.
Bala V; Rao S; Li P; Wang S; Prestidge CA
Mol Pharm; 2016 Jan; 13(1):287-94. PubMed ID: 26623947
[TBL] [Abstract][Full Text] [Related]
16. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
Gu Y; Ma J; Fu Z; Xu Y; Gao B; Yao J; Xu W; Chu K; Chen J
Int J Nanomedicine; 2019; 14():8805-8818. PubMed ID: 31806973
[TBL] [Abstract][Full Text] [Related]
17. Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.
Sepehri N; Rouhani H; Ghanbarpour AR; Gharghabi M; Tavassolian F; Amini M; Ostad SN; Ghahremani MH; Dinarvand R
Biomed Res Int; 2014; 2014():963507. PubMed ID: 24895635
[TBL] [Abstract][Full Text] [Related]
18. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
19. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
20. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin.
Si J; Zhao X; Gao S; Huang D; Sui M
Int J Pharm; 2019 Sep; 568():118499. PubMed ID: 31299338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]